AC-262536
AC-262536 (AC-262,536) is an experimental non-steroidal SARM originally studied by Acadia Pharmaceuticals for benign prostatic hyperplasia and possible cognitive applications. It acts as a partial agonist at the androgen receptor with anabolic activity in animal models but has no human efficacy or safety data.
01 Overview
AC-262536 was investigated as a partial androgen receptor agonist, with early interest in prostate and central-nervous-system indications. In rodent models it showed anabolic effects on muscle and bone with weaker androgenic action on the prostate than testosterone.
There are no controlled human trials of AC-262536. It circulates in the research-chemical market where dosing and claims are anecdotal. Because it is a partial agonist, real-world potency for physique or performance goals is uncertain and likely lower than fuller agonists.
02 Mechanism
Partial agonist of the androgen receptor, producing tissue-selective anabolic signalling in muscle and bone with reduced activity in reproductive tissues in preclinical models.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 15–30 mg/day | Oral | No validated human dose; figures reflect grey-market anecdote. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Lean mass gainAnabolic effect on skeletal muscle demonstrated in rodent assays. | Preclinical | ||
| Bone-anabolic effectIncreased bone parameters in animal models. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPTA suppressionTestosterone suppression is expected of AR agonists; magnitude in humans is unmeasured. | Moderate | Reported | Anecdotal | |
| Uncharacterised toxicityNo human safety data on liver, lipids, or cardiovascular endpoints. | Moderate | Uncharacterised | Unconfirmed |